The cohort consisted of 50 CP-CML patients who had received imatinib treatment for >12 months and achieved at least a Major Cytogenic Response (MCyR) but were still BCR::ABL1+ by qPCR analysis. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.